lobbying_filings_raw: fe475758-bcd3-4425-91d4-f201dfa8dcc5
This data as json
| filing_uuid | filing_type | registrant_id | registrant_name | client_id | client_name | filing_year | filing_period | received_date | is_amendment | is_no_activity | is_termination | raw_json | registrant_state | registrant_country | registrant_house_id | client_state | client_ppb_state | client_country | client_ppb_country | client_general_description | client_government_entity | affiliated_org_count | client_entity_id | client_government_unit_id | client_match_method | client_match_confidence | income_amount | expense_amount |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| fe475758-bcd3-4425-91d4-f201dfa8dcc5 | Q1 | 401104864 | AMERICAN SOCIETY OF ADDICTION MEDICINE | 202836 | AMERICAN SOCIETY OF ADDICTION MEDICINE | 2025 | first_quarter | 2025-04-18T06:45:22-04:00 | 0 | 0 | 0 | {"url": "https://lda.gov/api/v1/filings/fe475758-bcd3-4425-91d4-f201dfa8dcc5/", "filing_uuid": "fe475758-bcd3-4425-91d4-f201dfa8dcc5", "filing_type": "Q1", "filing_type_display": "1st Quarter - Report", "filing_year": 2025, "filing_period": "first_quarter", "filing_period_display": "1st Quarter (Jan 1 - Mar 31)", "filing_document_url": "https://lda.gov/filings/public/filing/fe475758-bcd3-4425-91d4-f201dfa8dcc5/print/", "filing_document_content_type": "text/html", "income": null, "expenses": "50000.00", "expenses_method": "A", "expenses_method_display": "A", "posted_by_name": "Kelly Corredor", "dt_posted": "2025-04-18T06:45:22-04:00", "termination_date": null, "registrant_country": "United States of America", "registrant_ppb_country": null, "registrant_address_1": "11400 Rockville Pike", "registrant_address_2": null, "registrant_different_address": false, "registrant_city": "Rockville", "registrant_state": "MD", "registrant_zip": "20852", "registrant": {"id": 401104864, "url": "https://lda.gov/api/v1/registrants/401104864/", "house_registrant_id": null, "name": "AMERICAN SOCIETY OF ADDICTION MEDICINE", "description": "Medical Professional Society", "address_1": "11400 Rockville Pike", "address_2": null, "address_3": null, "address_4": null, "city": "Rockville", "state": "MD", "state_display": "Maryland", "zip": "20852", "country": "US", "country_display": "United States of America", "ppb_country": "US", "ppb_country_display": "United States of America", "contact_name": "CAROLYN C. LANHAM", "contact_telephone": "+1 301-547-4104", "dt_updated": "2026-01-13T15:06:19.564018-05:00"}, "client": {"id": 202836, "url": "https://lda.gov/api/v1/clients/202836/", "client_id": 12, "name": "AMERICAN SOCIETY OF ADDICTION MEDICINE", "general_description": "Medical Professional Society", "client_government_entity": false, "client_self_select": true, "state": "MD", "state_display": "Maryland", "country": "US", "country_display": "United States of America", "ppb_state": "MD", "ppb_state_display": "Maryland", "ppb_country": "US", "ppb_country_display": "United States of America", "effective_date": "2018-05-01"}, "lobbying_activities": [{"general_issue_code": "ALC", "general_issue_code_display": "Alcohol and Drug Abuse", "description": "Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS: Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria. Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders. Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products. Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis. Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in inflation. Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for amending DEA regulations to allow qualified practitioners to prescribe methadone for OUD for pharmacy administration/dispensing. Advocated for HR 2586- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Supported HR 1510 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Sent letter to DEA that underscored ASAM's support for the Expansion of Buprenorphine Treatment via Telemedicine Encounter final rule. Sent comment letter to DEA and DOJ regarding the Special Registrations for Telemedicine and Limited State Telemedicine Registrations proposed rule. In the comment letter, ASAM provides two key recommendations to improve the rule. This includes recommending that the DEA add another prescribing eligibility category for practitioners who are addiction medicine physicians or board certified in the treatment of addiction. Endorsed the TREATS Act (HR 1627) to amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment, and for other purposes. Endorsed S. 1036, improving access to addiction medicine providers by amending the Public Health Service Act to authorize fellowships under the Minority Fellowship Program to be awarded for training for professionals in the addiction medicine field. Endorsed the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (S 931/ HR 2509), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. Lobbied to raise federal alcohol taxes", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 68378, "prefix": null, "prefix_display": null, "first_name": "KELLY", "nickname": null, "middle_name": null, "last_name": "CORREDOR", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 136, "name": "Centers For Medicare and Medicaid Services (CMS)"}, {"id": 8, "name": "Congressional Budget Office (CBO)"}, {"id": 155, "name": "Drug Enforcement Administration (DEA)"}, {"id": 135, "name": "Food & Drug Administration (FDA)"}, {"id": 34, "name": "Health & Human Services, Dept of (HHS)"}, {"id": 137, "name": "Health Resources & Services Administration (HRSA)"}, {"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 19, "name": "Office of Natl Drug Control Policy (NDCP)"}, {"id": 1, "name": "SENATE"}, {"id": 141, "name": "Substance Abuse & Mental Health Services Administration (SAMHSA)"}]}, {"general_issue_code": "HCR", "general_issue_code_display": "Health Issues", "description": "Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS: Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria. Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders. Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products. Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis. Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in inflation. Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for amending DEA regulations to allow qualified practitioners to prescribe methadone for OUD for pharmacy administration/dispensing. Advocated for HR 2586- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Supported HR 1510 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Sent letter to DEA that underscored ASAM's support for the Expansion of Buprenorphine Treatment via Telemedicine Encounter final rule. Sent comment letter to DEA and DOJ regarding the Special Registrations for Telemedicine and Limited State Telemedicine Registrations proposed rule. In the comment letter, ASAM provides two key recommendations to improve the rule. This includes recommending that the DEA add another prescribing eligibility category for practitioners who are addiction medicine physicians or board certified in the treatment of addiction. Endorsed the TREATS Act (HR 1627) to amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment, and for other purposes. Endorsed S. 1036, improving access to addiction medicine providers by amending the Public Health Service Act to authorize fellowships under the Minority Fellowship Program to be awarded for training for professionals in the addiction medicine field. Endorsed the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (S 931/ HR 2509), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. Lobbied to raise federal alcohol taxes", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 68378, "prefix": null, "prefix_display": null, "first_name": "KELLY", "nickname": null, "middle_name": null, "last_name": "CORREDOR", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 136, "name": "Centers For Medicare and Medicaid Services (CMS)"}, {"id": 8, "name": "Congressional Budget Office (CBO)"}, {"id": 155, "name": "Drug Enforcement Administration (DEA)"}, {"id": 135, "name": "Food & Drug Administration (FDA)"}, {"id": 34, "name": "Health & Human Services, Dept of (HHS)"}, {"id": 137, "name": "Health Resources & Services Administration (HRSA)"}, {"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 19, "name": "Office of Natl Drug Control Policy (NDCP)"}, {"id": 1, "name": "SENATE"}, {"id": 141, "name": "Substance Abuse & Mental Health Services Administration (SAMHSA)"}]}, {"general_issue_code": "MED", "general_issue_code_display": "Medical/Disease Research/Clinical Labs", "description": "Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS: Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria. Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders. Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products. Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis. Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in inflation. Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for amending DEA regulations to allow qualified practitioners to prescribe methadone for OUD for pharmacy administration/dispensing. Advocated for HR 2586- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Supported HR 1510 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Sent letter to DEA that underscored ASAM's support for the Expansion of Buprenorphine Treatment via Telemedicine Encounter final rule. Sent comment letter to DEA and DOJ regarding the Special Registrations for Telemedicine and Limited State Telemedicine Registrations proposed rule. In the comment letter, ASAM provides two key recommendations to improve the rule. This includes recommending that the DEA add another prescribing eligibility category for practitioners who are addiction medicine physicians or board certified in the treatment of addiction. Endorsed the TREATS Act (HR 1627) to amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment, and for other purposes. Endorsed S. 1036, improving access to addiction medicine providers by amending the Public Health Service Act to authorize fellowships under the Minority Fellowship Program to be awarded for training for professionals in the addiction medicine field. Endorsed the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (S 931/ HR 2509), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. Lobbied to raise federal alcohol taxes", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 68378, "prefix": null, "prefix_display": null, "first_name": "KELLY", "nickname": null, "middle_name": null, "last_name": "CORREDOR", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 136, "name": "Centers For Medicare and Medicaid Services (CMS)"}, {"id": 8, "name": "Congressional Budget Office (CBO)"}, {"id": 155, "name": "Drug Enforcement Administration (DEA)"}, {"id": 135, "name": "Food & Drug Administration (FDA)"}, {"id": 34, "name": "Health & Human Services, Dept of (HHS)"}, {"id": 137, "name": "Health Resources & Services Administration (HRSA)"}, {"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 19, "name": "Office of Natl Drug Control Policy (NDCP)"}, {"id": 1, "name": "SENATE"}, {"id": 141, "name": "Substance Abuse & Mental Health Services Administration (SAMHSA)"}]}, {"general_issue_code": "MMM", "general_issue_code_display": "Medicare/Medicaid", "description": "Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS: Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria. Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders. Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products. Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis. Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in inflation. Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for amending DEA regulations to allow qualified practitioners to prescribe methadone for OUD for pharmacy administration/dispensing. Advocated for HR 2586- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Supported HR 1510 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Sent letter to DEA that underscored ASAM's support for the Expansion of Buprenorphine Treatment via Telemedicine Encounter final rule. Sent comment letter to DEA and DOJ regarding the Special Registrations for Telemedicine and Limited State Telemedicine Registrations proposed rule. In the comment letter, ASAM provides two key recommendations to improve the rule. This includes recommending that the DEA add another prescribing eligibility category for practitioners who are addiction medicine physicians or board certified in the treatment of addiction. Endorsed the TREATS Act (HR 1627) to amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment, and for other purposes. Endorsed S. 1036, improving access to addiction medicine providers by amending the Public Health Service Act to authorize fellowships under the Minority Fellowship Program to be awarded for training for professionals in the addiction medicine field. Endorsed the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (S 931/ HR 2509), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. Lobbied to raise federal alcohol taxes", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 68378, "prefix": null, "prefix_display": null, "first_name": "KELLY", "nickname": null, "middle_name": null, "last_name": "CORREDOR", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 136, "name": "Centers For Medicare and Medicaid Services (CMS)"}, {"id": 8, "name": "Congressional Budget Office (CBO)"}, {"id": 155, "name": "Drug Enforcement Administration (DEA)"}, {"id": 135, "name": "Food & Drug Administration (FDA)"}, {"id": 34, "name": "Health & Human Services, Dept of (HHS)"}, {"id": 137, "name": "Health Resources & Services Administration (HRSA)"}, {"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 19, "name": "Office of Natl Drug Control Policy (NDCP)"}, {"id": 1, "name": "SENATE"}, {"id": 141, "name": "Substance Abuse & Mental Health Services Administration (SAMHSA)"}]}, {"general_issue_code": "BUD", "general_issue_code_display": "Budget/Appropriations", "description": "Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS: Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria. Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders. Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products. Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis. Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in inflation. Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for amending DEA regulations to allow qualified practitioners to prescribe methadone for OUD for pharmacy administration/dispensing. Advocated for HR 2586- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Supported HR 1510 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Sent letter to DEA that underscored ASAM's support for the Expansion of Buprenorphine Treatment via Telemedicine Encounter final rule. Sent comment letter to DEA and DOJ regarding the Special Registrations for Telemedicine and Limited State Telemedicine Registrations proposed rule. In the comment letter, ASAM provides two key recommendations to improve the rule. This includes recommending that the DEA add another prescribing eligibility category for practitioners who are addiction medicine physicians or board certified in the treatment of addiction. Endorsed the TREATS Act (HR 1627) to amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment, and for other purposes. Endorsed S. 1036, improving access to addiction medicine providers by amending the Public Health Service Act to authorize fellowships under the Minority Fellowship Program to be awarded for training for professionals in the addiction medicine field. Endorsed the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (S 931/ HR 2509), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. Lobbied to raise federal alcohol taxes", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 68378, "prefix": null, "prefix_display": null, "first_name": "KELLY", "nickname": null, "middle_name": null, "last_name": "CORREDOR", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 136, "name": "Centers For Medicare and Medicaid Services (CMS)"}, {"id": 8, "name": "Congressional Budget Office (CBO)"}, {"id": 155, "name": "Drug Enforcement Administration (DEA)"}, {"id": 135, "name": "Food & Drug Administration (FDA)"}, {"id": 34, "name": "Health & Human Services, Dept of (HHS)"}, {"id": 137, "name": "Health Resources & Services Administration (HRSA)"}, {"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 19, "name": "Office of Natl Drug Control Policy (NDCP)"}, {"id": 1, "name": "SENATE"}, {"id": 141, "name": "Substance Abuse & Mental Health Services Administration (SAMHSA)"}]}, {"general_issue_code": "INS", "general_issue_code_display": "Insurance", "description": "Submitted comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding its calendar year 2026 Medicare Advantage (MA) and Part D proposed rule, recommending that CMS: Finalize proposals to limit cost-sharing in MA and Medicare cost plans (cost plans) to no more than the amounts allowed in traditional Medicare in contract year 2026; Collect data on the impact of these cost-sharing limits on plan contracting arrangements with clinicians; Determine whether the proposed cost-sharing limits may be applied to medications to treat addiction; Finalize proposal to ensure MA provider directories are included in the Medicare plan finder by 2026 and be updated on a regular basis; and Finalize proposed updates to regulations governing internal coverage criteria. Joined coalition letters/sent letters to/lobbied Congress, urging them to protect Medicaid for individuals with mental health conditions and substance use disorders. Joined coalition letter to leadership of the House and Senate Committees on Appropriations urging them to ensure that final appropriations bills for fiscal year 2025 allow the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to retain their respective oversight authorities over tobacco related products and receive key resources to protect children from such products. Lobbied/sent letter to Congress urging for the inclusion of key amendments to the Halt Lethal Trafficking (HALT) Fentanyl Act (S. 331/HR 27). These amendments would mitigate unintended negative consequences of the bill and encourage further Congressional action to address the demand side of the countrys national addiction and overdose crisis. Joined coalition letter to House and Senate leadership calling for the inclusion of the bipartisan Medicare Patient Access and Practice Stabilization Act (H.R. 879) in the forthcoming appropriations bill. The bill would put a stop to the latest round of payment cuts and give physicians a two percent payment increase to keep up with the rise in inflation. Advocated for increased FY26 funding for HRSA's Addiction Medicine Fellowship Program ($30M) Advocated for increased FY26 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M). Advocated for amending DEA regulations to allow qualified practitioners to prescribe methadone for OUD for pharmacy administration/dispensing. Advocated for HR 2586- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration Supported HR 1510 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes. Advocated for reintroduction of Residential Recovery for Seniors Act. This first-of-its-kind legislation would create a Medicare Part A benefit for residential addiction treatment programs meeting nationally recognized standards, categorized as Level 3.1: Clinically Managed Low-intensity Residential Treatment; Level 3.5: Clinically Managed High-intensity Residential Treatment, and/or Level 3.7: Medically Managed Residential Treatment. It would also establish a prospective payment system for these programs, ensuring that reimbursement for covered residential addiction treatment services is based on pre-determined, fixed amounts. Sent letter to DEA that underscored ASAM's support for the Expansion of Buprenorphine Treatment via Telemedicine Encounter final rule. Sent comment letter to DEA and DOJ regarding the Special Registrations for Telemedicine and Limited State Telemedicine Registrations proposed rule. In the comment letter, ASAM provides two key recommendations to improve the rule. This includes recommending that the DEA add another prescribing eligibility category for practitioners who are addiction medicine physicians or board certified in the treatment of addiction. Endorsed the TREATS Act (HR 1627) to amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment, and for other purposes. Endorsed S. 1036, improving access to addiction medicine providers by amending the Public Health Service Act to authorize fellowships under the Minority Fellowship Program to be awarded for training for professionals in the addiction medicine field. Endorsed the Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (S 931/ HR 2509), which would encourage the adoption of integrated delivery models that will make behavioral health services more accessible to patients. It would do this through a temporary increase in Medicare reimbursement rates for integrated care codes. Lobbied to raise federal alcohol taxes", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 68378, "prefix": null, "prefix_display": null, "first_name": "KELLY", "nickname": null, "middle_name": null, "last_name": "CORREDOR", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 136, "name": "Centers For Medicare and Medicaid Services (CMS)"}, {"id": 8, "name": "Congressional Budget Office (CBO)"}, {"id": 155, "name": "Drug Enforcement Administration (DEA)"}, {"id": 135, "name": "Food & Drug Administration (FDA)"}, {"id": 34, "name": "Health & Human Services, Dept of (HHS)"}, {"id": 137, "name": "Health Resources & Services Administration (HRSA)"}, {"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 19, "name": "Office of Natl Drug Control Policy (NDCP)"}, {"id": 1, "name": "SENATE"}, {"id": 141, "name": "Substance Abuse & Mental Health Services Administration (SAMHSA)"}]}], "conviction_disclosures": [], "foreign_entities": [], "affiliated_organizations": []} | MD | US | MD | MD | US | US | Medical Professional Society | 0 | 0 | 50000.0 |